Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to “Strong-Buy” at Cantor Fitzgerald
Cantor Fitzgerald upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) to a strong-buy rating in a research report sent to investors on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Aclaris Therapeutics’ FY2025 earnings at ($0.54) EPS. Several other equities research analysts also recently issued reports on ACRS. HC Wainwright raised Aclaris Therapeutics from […]
Cantor Fitzgerald upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) to a strong-buy rating in a research report sent to investors on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Aclaris Therapeutics’ FY2025 earnings at ($0.54) EPS. Several other equities research analysts also recently issued reports on ACRS. HC Wainwright raised Aclaris Therapeutics from […]
